Kang, G., Hu, M., Ren, H., Wang, J., Cheng, X., Li, R., . . . Huang, H. (2021, August). VHH212 nanobody targeting the hypoxia-inducible factor 1α suppresses angiogenesis and potentiates gemcitabine therapy in pancreatic cancer in vivo. Cancer Biology & Medicine.
Chicago Style (17th ed.) CitationKang, Guangbo, et al. "VHH212 Nanobody Targeting the Hypoxia-inducible Factor 1α Suppresses Angiogenesis and Potentiates Gemcitabine Therapy in Pancreatic Cancer in Vivo." Cancer Biology & Medicine Aug. 2021.
MLA (9th ed.) CitationKang, Guangbo, et al. "VHH212 Nanobody Targeting the Hypoxia-inducible Factor 1α Suppresses Angiogenesis and Potentiates Gemcitabine Therapy in Pancreatic Cancer in Vivo." Cancer Biology & Medicine, Aug. 2021.
Warning: These citations may not always be 100% accurate.